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OBJECTIVES: To determine the rate of return to work
post-MI; and for returnees, self-reported work perfor-
mance and number of days absent. METHODS: Patients
admitted to the University of Michigan Medical Center
with diagnosis of MI were identified consecutively and
prospectively from October 1999 to May 2000. Clinical
data were obtained retrospectively from medical records.
Six months after discharge, patients were interviewed by
telephone to determine work status prior to and after MI.
Work-related outcomes included self-reported work per-
formance using the Work Performance Scale (WP, 1 
lowest, 4  highest performance) and number of days ab-
sent. The SF-12 was administered to determine physical
(PCS-12) and mental (MCS-12) functional status. RE-
SULTS: Of 202 patients interviewed, 30.2% worked
prior to the reference MI. Of these, 80.3% were male,
mean age was 56.1 years, and 26.2% did not return to
work. Those not returning had lower median PCS-12
scores (28.5 versus 42.8 for returnees, p  0.001), prior
MI (62.5% versus 17.8% for returnees, p  0.003), and
history of congestive heart failure (25.0% versus 4.4%
for returnees, p  0.03). Returnees had a median WP of
3.6, and 82.2% indicated no absences. Median WP
scores were lower for patients with lower ejection frac-
tions (EF) (3.2 for EF  40% versus 3.8 for EF3  40%,
p  0.01), hypertension (3.5 versus 3.8 without hyper-
tension, p  0.02), or prior MI (3.3 versus 3.8 without
previous MI, p  0.01). Workers reporting absences had
lower EF (40% EF  40% versus 11.4% EF  40% for
no absences, p  0.05), lower median PCS-12 score (31.1
versus 44.5 for no absences, p  0.02), and prior MI
(50.0% versus 10.8% if no absences, p  0.02). CON-
CLUSIONS: Preexisting cardiac disease, lower EF at dis-
charge, and poorer physical functioning were negatively
related to work-related outcomes. This small study dem-
onstrates the need for a larger, broader study that in-
cludes, health beliefs, psychosocial assessment, treatment,
and other job/patient factors that may influence work-
related outcomes.
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OBJECTIVES: To determine the relationship between di-
abetes symptom burden and patients’ perceptions of
health-related quality of life (HRQL). METHODS: A
questionnaire was sent to 3,716 adults with diabetes en-
rolled in a managed care organization in West Virginia
and southeastern Ohio. Diabetes symptom burden was
measured using a 17-item scale (Diabetes TyPE, Form
2.1). The Health Status Questionaire (HSQ-12), Version
3.0 was utilized to measure patients’ perception of their
HRQL. Analyses focused on six domains from the HSQ-
12: General Health Perception (GHP), Physical Function-
ing (PF), Bodily Pain (BP), Energy/Fatigue (EF), Social
Functioning (SF), and Mental Health (MH). Linear re-
gression was used to examine the impact of diabetes
symptoms on each of the HRQL domains. RESULTS:
Usable responses were obtained from 1,027 persons with
diabetes (27.6% response rate). The summated scale of
diabetes symptom burden had acceptable internal consis-
tency (alpha  0.90). Analyses revealed a significant in-
verse relationship between diabetes symptom burden and
each of the six domains from the HSQ-12, when control-
ling for gender, age, and education. Overall symptom
burden was found to be most highly associated with So-
cial Functioning (r  .57), while somewhat less
strongly associated with the other five domains: GHP
(r  .52); PF (r  .49); BP (r  .51); EF (r  .54);
MH (r  .50). As overall symptom burden increases,
the patients’ perception of health across all six HRQL
domains decreases. CONCLUSIONS: Diabetes symptom
burden is inversely related to health-related quality of
life. Thus, interventions targeted towards the alleviation
of diabetes symptoms should also lead to improvements
in patients’ perceptions of their health and well-being.
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OBJECTIVES: The cost and management of patients
with multiple chronic conditions present unique chal-
lenges to the health care system. Major chronic condi-
tions such as diabetes often co-occur with other chronic
illnesses. The objective of this study is to report the incre-
mental cost of diabetes mellitus when it co-occurs with
cardiovascular conditions, depression, hypertension, psy-
chosis, respiratory/asthma, or acid peptic disease. METH-
ODS: A one-year retrospective database analysis using an
integrated Medicaid dataset from the State of Oklahoma.
Disease states were identified by ICD-9-CM codes and a
validated drug-based classification. Patients included in
the study had the chronic condition identified by both
drug and diagnosis information. The incremental costs of
diabetes when co-occurring with other chronic condi-
tions was determined by subtracting the cost of the non-
diabetes single condition from the co-occurring disease
group. RESULTS: Seven groups of patients consisted of;
diabetes only (n  1038), diabetes co-occurring with hy-
pertension (n  313), respiratory illness/asthma (n  62),
depression (n  48), cardiovascular illness (n  35), psy-
chosis (n  35), and acid peptic disease (n  30). Diabe-
tes as a single chronic illness had an annual cost of $818
over patients with no evidence of chronic illness. The in-
cremental cost of diabetes when co-occurring with psy-
chosis was $7,211, respiratory illness/asthma $3,161, hy-
pertension $1,595, depression $1,319, acid peptic disease
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$977, and cardiovascular illness $35. The incremental
cost of diabetes co-occurring with psychosis was signifi-
cantly higher than all other disease co-occurrences. Dif-
ferences in the incremental cost of diabetes were not sta-
tistically significant between the other disease combinations.
ANCOVA was performed with longevity in the program
as a covariate to adjust for differential enrollment time.
CONCLUSION: The cost and management of chronic
conditions such as diabetes may be highly influenced by
other chronic conditions the patient may have. Disease
management programs may incorporate co-morbidity re-
search and models when evaluating the cost and treat-
ment of chronic conditions.
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OBJECTIVE: To obtain a profile of adult patients at risk
for nonsteroidal anti-inflammatory drug (NSAID) in-
duced gastrointestinal (GI) complications in a large man-
aged care health plan in the Southwest United States.
METHODS: Patients with NSAID prescription claims
between July 1996 and June 1997 were identified from a
health plan claims database. Patients with claims associ-
ated with ICD-9 and CPT codes indicating serious GI
complications were then identified. The ICD-9 codes
used were those associated with GI ulcers (531.x, 532.x,
533.x, and 534). A total of 19 CPT codes for GI proce-
dures indicative of a GI complication were used. A for-
ward stepwise logistic regression analysis, using the likeli-
hood-ratio (LR) test, was performed to identify predictors
of GI complications. Predictors included in the model
were individual NSAIDs and the following potential risk
factors: age, gender, previous GI drug usage, previous
steroid usage, and total days supply of NSAIDs during
the study period. RESULTS: A sample of 15,772 patients
with prescription claims for NSAIDs was identified. Of
these patients, 213 (1.4%) had an ICD-9 or CPT code
suggestive of serious GI complications secondary to a
NSAID. The logistic regression results indicated that
women (OR  0.65, 95% CI  0.48–0.87) were less
likely to develop GI complications. However, patients
with previous GI drug usage (OR  5.97, 95% CI 
4.51–7.90), those who used ketorolac (OR  2.01, 95%
CI  1.10–3.67) and those who used oxaprozin (OR 
1.82, 95% CI  1.10–3.00) were more likely to develop
GI complications. CONCLUSION: Users of ketorolac
and oxaprozin, as well as those with previous GI drug us-
age were at a higher risk, while women were at a lower
risk of GI complications in this managed care population.
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OBJECTIVES: The primary objective was to describe the
cost of illness of gastroesophageal reflux disease (GERD)
in a managed care population. Secondary objectives were
to characterize GERD costs and to quantify the depen-
dence of costs on disease severity. METHODS: This ret-
rospective study utilized claims data from a large (1.4
million lives) Midwest USA health care plan. Study popu-
lation had complete medical and pharmacy coverage con-
tinuously from 1996 to 1998 and possessed at least one
medical claim for GERD. Claim costs were compiled for
all GERD-attributable medical and drug claims. Costs
were also categorized by health care sector, such as hos-
pital inpatient or pharmacy. ICD-9 codes were used to
categorize subjects’ GERD into four progressively worse
states plus a non-symptomatic state: GERD0 {no GERD
claims}, GERD1 {mild esophagitis}, GERD2 {reflux esoph-
agitis}, GERD3 {esophageal ulceration}, and GERD4 {stric-
tures and complications}. RESULTS: A total of 7575 sub-
jects meeting the inclusion and exclusion criteria were
identified. The median age was 50 and there were 50%
females. Over the three year study period, more than $23
million was spent on GERD-related claims, or $86 per
subject per month. Pharmacotherapy contributed 31% of
GERD health care costs, inpatient hospital charges 37%,
outpatient facility charges 26%, and doctor office charges
6%. Mean cost per month was highly dependent on GERD
disease state: GERD0 cost $38 per month, GERD1 was
$189, GERD2 was $232, GERD3 was $536, and GERD4
was $412. At higher GERD states, pharmacotherapy was
a lower contributor to cost. CONCLUSIONS: For payers
of health care, GERD is an expensive disorder to manage.
Overall costs associated with GERD increase with the se-
verity of the disease, although the relative contribution of
each health care cost sector changes with disease severity.
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OBJECTIVE: To model the relationship between resis-
tance to trimethoprim sulphamethoxazole (TMP-SXT)
